Avanir prevails in patent case

The U.S. District Court for the District of Delaware rules in favor of Avanir Pharmaceuticals (AVNR +1.5%) in its patent infringement case against Par Pharmaceuticals and Impax Laboratories (IPXL -1.3%) regarding their ANDAs for generic versions of Nuedexta.

The judge upheld the validity of patents '282 and '484 and ruled the proposed formulations infringe on both of them.

Nuedexta is the only FDA-approved product for the treatment of pseudobulbar effect. Based on the court's decision, the product has 12 years of market exclusivity remaining.

Comments (2)
  • fidelity comment
    , contributor
    Comments (244) | Send Message
    This happened last week and was reported on by SA. What new news has occurred to issue the current blurb?


    5 May 2014, 04:48 PM Reply Like
  • Leont68
    , contributor
    Comments (1421) | Send Message
    today, they formally filed a 8k announcing the win. http://bit.ly/1lSGVep
    5 May 2014, 04:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs